Pharvaris Company Research Report
Company Overview
Name
Pharvaris
Mission of the Company
Pharvaris aims to develop novel, oral alternatives that improve the standard of care for people living with hereditary angioedema (HAE).
Founding and Founders
No information is available.
Key People
- Berndt Modig - Chief Executive Officer, Director
- Stefan Abele, Ph.D. - Chief Technical Operations Officer
- Annick Deschoolmeester - Chief Human Resources Officer
- Anne Lesage, Ph.D. - Chief Early Development Officer
- Peng Lu, M.D., Ph.D. - Chief Medical Officer
- David Nassif, J.D. - Chief Financial Officer
- Wim Souverijns, Ph.D. - Chief Commercial Officer
- Anna Nijdam - Head, Strategic Finance and Principal Accounting Officer
- Jochen Knolle, Ph.D. - Strategic Advisor
- Board of Directors:
- David Meeker, M.D. - Chair of the Board
- Elisabeth Björk, M.D. - Director
- Robert Glassman, M.D. - Director
- Viviane Monges - Director, Audit Chair
- Hans Schikan, Pharm.D. - Vice Chair of the Board
Headquarters
No information is available.
Number of Employees
No information is available.
Revenue
No information is available.
Company Recognition
Pharvaris is known for being a leader in bradykinin-mediated diseases, aiming to deliver effective, safe, and easy to administer therapies.
Products
Deucrictibant
Pharvaris' focus is on the development of deucrictibant, which is a small molecule antagonist targeting the bradykinin B2 receptor.
High-level Description
Deucrictibant exists in two distinct oral formulations - an immediate-release capsule for the acute treatment of HAE attacks and an extended-release tablet for the prophylactic treatment of HAE.
Key Features
- Immediate-release capsule for on-demand treatment.
- Extended-release tablet for prophylactic treatment with sustained therapeutic exposure over 24 hours.
PHVS719 (Deucrictibant Extended-Release Tablet)
- Key Feature: Maintains sustained therapeutic exposure over 24 hours allowing for once-daily oral treatment to prevent HAE attacks.
Recent Developments
Clinical Trials
- CHAPTER-3: A pivotal Phase 3 randomized clinical trial evaluating the efficacy and safety of a once-daily oral drug (deucrictibant extended-release tablet) compared to placebo in preventing HAE attacks.
- RAPIDe-3: Pivotal Phase 3 study of deucrictibant for on-demand treatment of HAE attacks.
- CHAPTER-4: Extension study evaluating the safety and efficacy of deucrictibant as a preventative daily treatment for HAE.
Partnerships
No information is available.
New Features
No information is available on new features added to existing products.
Publications and Presentations
- International Immunopharmacology: Pharmacological profile of PHA121.
- Frontiers in Pharmacology: In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist.
- Presentation: Efficacy and Safety of Oral Deucrictibant in Prophylaxis of Hereditary Angioedema Attacks.
- Poster: Relief and Resolution of Attack Symptoms following on-demand treatment with a single dose of oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule.
Conclusion
The report provides an overview of Pharvaris, a clinical-stage company pioneering oral treatments for hereditary angioedema (HAE) by focusing on novel bradykinin B2 receptor antagonists. Currently, their main product, deucrictibant, is undergoing clinical trials for both on-demand and prophylactic treatment of HAE, highlighting their commitment to offering more convenient and effective oral treatment options for patients.
